Finally, we found that treatment with epigenome-related nucleosides such as 5fdC are a promising therapeutic strategy for overcoming ALK inhibitor resistance in CDA-overexpressing NSCLC. This evidence concerns the gene ALK and non-small cell lung carcinoma.